Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | FABP4 | P15090 | 2/20 | 0.65 |
| ▸ | SLC16A3 | O15427 | 3/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.59 |
| ▸ | CA12 | O43570 | 2/20 | 0.56 |
| ▸ | CA9 | Q16790 | 2/20 | 0.56 |
| ▸ | NSD2 | O96028 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.51 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20026077 | 0.87 | NSD2 (0.70) | NPY5RCA12CA9NSD2CCR8 | |
| Hydrochloric Acid SCHEMBL6909699 | 0.84 | FABP4 (0.51) | TSHRFABP4SLC16A3NPY5RCA12 | |
| SCHEMBL4449327 | 0.84 | NSD2 (0.76) | FABP4CA12CA9NSD2CCR8 | |
| Hydrochloric Acid SCHEMBL4443333 | 0.83 | NSD2 (0.76) | FABP4NSD2CCR8 | |
| SCHEMBL7457681 | 0.83 | NPY5R (0.64) | NPY5RCA9NSD2 | |
| SCHEMBL3559856 | 0.81 | TSHR (0.85) | TSHRFABP4SLC16A3P4HTM | |
| SCHEMBL4444940 | 0.80 | FABP4 (0.60) | FABP4SLC16A3NSD2KMT2ACCR8 | |
| SCHEMBL15762086 | 0.79 | TSHR (1.00) | TSHRFABP4SLC16A3P4HTM | |
| SCHEMBL8891919 | 0.79 | CA12 (0.52) | FABP4NPY5RCA12NSD2 | |
| SCHEMBL29162296 | 0.78 | NSD2 (0.73) | FABP4NPY5RNSD2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444120-B1 | Spirocyclic amiloride analogues as ENac blockers | NOVARTIS AG (CH) | 2017-09-27 | — | — | EP | disclosed |
| US-9643983-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2017-05-09 | — | — | US | disclosed |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9139586-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2015-09-22 | — | — | US | disclosed |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMACEUTICALS INCORPORATED | 2015-06-04 | — | — | US | disclosed |
| EP-2813227-A1 | Compositions for treatment of cystic fibrosis and other chronic diseases | Vertex Pharmaceuticals Incorporated (US) | 2014-12-17 | — | — | EP | disclosed |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | VERTEX PHARMA (US) | 2014-11-06 | — | — | US | disclosed |
| CN-101939054-B | organic compounds | NOVARTIS AG (CH) | 2014-10-29 | — | — | CN | disclosed |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2014-06-19 | — | — | US | disclosed |
| US-8697687-B2 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2014-04-15 | — | — | US | disclosed |
| US-20130012500-A1 | ORGANIC COMPOUNDS | BHALAY GURDIP (GB) | 2013-01-10 | — | — | US | disclosed |
| EP-2520574-A1 | Amiloride analogues substituted on the cyclic guanidine moiety as ENaC blockers for treating respiratory diseases | Novartis AG (CH) | 2012-11-07 | — | — | EP | disclosed |
| CN-102665715-A | Compositions for treatment of cystic fibrosis and other chronic diseases | VERTEX PHARMA | 2012-09-12 | — | — | CN | disclosed |
| EP-2444120-A1 | Spirocyclic amiloride analogues as ENac blockers | Novartis AG (CH) | 2012-04-25 | — | — | EP | disclosed |
| US-8039472-B2 | Pyrazine-2-carboxamide derivatives to treat diseases mediated by blockade of the epithelial sodium channel | NOVARTIS AG (CH) | 2011-10-18 | — | — | US | disclosed |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | NOVARTIS AG (CH) | 2011-09-29 | — | — | US | disclosed |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | Vertex Pharmaceuticals Incorported (US) | 2011-04-28 | — | — | US | disclosed |
| CN-101939054-A | Organic compounds | NOVARTIS AG | 2011-01-05 | — | — | CN | disclosed |
| US-20100130506-A1 | Organic Compounds | NOVARTIS AG | 2010-05-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012500-A1 | ORGANIC COMPOUNDS | OR10J3, REN, CACNA1E | TSHR 875/4885FABP4 2605/4885SLC16A3 574/4885 |
| US-20110098311-A1 | COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES | CFTR, SLC26A4, ABCB11 | TSHR 3893/4885FABP4 2499/4885SLC16A3 339/4885 |
| US-20140329814-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | TSHR 3893/4885FABP4 2499/4885SLC16A3 339/4885 |
| US-20110237572-A1 | Treating diseases mediated by blockade of the epithelial sodium channel with pyrazine-2-carboxamide derivatives | SCNN1B, SCNN1A, SCNN1G | TSHR 515/4885FABP4 3810/4885SLC16A3 502/4885 |
| US-20160068546-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | TSHR 515/4885FABP4 3810/4885SLC16A3 502/4885 |
| US-20150231142-A1 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | TSHR 3893/4885FABP4 2499/4885SLC16A3 339/4885 |
| US-20100130506-A1 | Organic Compounds | OR10J3, REN, CACNA1E | TSHR 875/4885FABP4 2605/4885SLC16A3 574/4885 |
| US-20150150879-A2 | Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases | CFTR, SLC26A4, ABCB11 | TSHR 3893/4885FABP4 2499/4885SLC16A3 339/4885 |
| US-20140171421-A1 | TREATING DISEASES MEDIATED BY BLOCKADE OF THE EPITHELIAL SODIUM CHANNEL WITH PYRAZINE-2-CARBOXAMIDE DERIVATIVES | SCNN1B, SCNN1A, SCNN1G | TSHR 515/4885FABP4 3810/4885SLC16A3 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.